News
GLP-1 RA helped resolution of steatohepatitis without worsening fibrosis and reduced liver fibrosis without worsening steatohepatitis.
On a quest to expand the eligible patient pool for its fast-growing liver disease drug Rezdiffra, Madrigal Pharmaceuticals ...
California biotech NGM Bio is slimming down as the company pivots focus, shedding around 75% of staff, pausing development of ...
18h
MyChesCo on MSNMadrigal Pharmaceuticals Reports Promising Two-Year Data for Rezdiffra in MASH CirrhosisCONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced two-year results from the open-label arm of ...
Phase 2b SYMMETRY study preliminary results showed statistically significant reversal of compensated cirrhosis (F4) due to ...
10h
Health on MSNRoad to Diagnosis: Patients Share Their MASH JourneysTwo patients with MASH share their paths to diagnosis, including the challenges they faced and what it took to find answers.
Data presentation included efficacy and biomarker analyses from the NAVIGATE trial (n=287). Belapectin 2 mg/kg demonstrated a statistically significant reduction in new varices at 18 months in the per ...
Analysts anticipate Altimmune to report an earnings per share (EPS) of $-0.34. The announcement from Altimmune is eagerly anticipated, with investors seeking news of surpassing estimates and favorable ...
From 2006 to 2019, age-adjusted mortality for liver disease in the US increased by 14% overall and by 24% during COVID, from 2019 through 2021.
For patients with metabolic dysfunction-associated steatohepatitis and fibrosis, semaglutide is associated with improved liver histologic outcomes.
which is linked to chronic liver disease. Liver inflammation contributes to conditions like fatty liver. Coriander's anti-inflammatory compounds can help calm this response and promote healing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results